A multi-center, Phase 3 study of lonafarnib (LNF) + ritonavir (RTV) and a combination arm of LNF + RTV + pegylated interferon-alfa (PEG IFN-α) in HDV-infected patients

Trial Profile

A multi-center, Phase 3 study of lonafarnib (LNF) + ritonavir (RTV) and a combination arm of LNF + RTV + pegylated interferon-alfa (PEG IFN-α) in HDV-infected patients

Planning
Phase of Trial: Phase III

Latest Information Update: 16 May 2018

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon alfa (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis D
  • Focus Registrational; Therapeutic Use
  • Acronyms D-LIVR
  • Sponsors Eiger BioPharmaceuticals, Inc.
  • Most Recent Events

    • 16 May 2018 According to Eiger BioPharmaceuticals media release, the company plans to initiate this trial by the end of the year.
    • 21 Mar 2018 According to Eiger BioPharmaceuticals media release, the company is currently defining primary and secondary endpoints with the FDA and plans to initiate the trial in 2H 2018.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top